Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insulet Wins FDA Clearance For Omnipod ACE Pump

Executive Summary

Diabetes company Insulet received US FDA clearance to market its Omnipod DASH alternate controller-enabled infusion pump as an integrated insulin pump.

You may also be interested in...



Market Intel: After A Year Of Partnerships, Insulin Pump Manufacturers Will Face Fierce Competition In 2020

The insulin pump market is expected to grow to $5.1bn by 2023, driven by the increasing incidence of diabetes and adoption of next-generation hybrid closed-loop systems, which allow patients and health-care providers to better manage care. This first part of a two-part series highlights the rising competitive landscape of the four major players, Medtronic, Insulet, Tandem Diabetes Care and Valeritas, with insights from endocrinologists. The second part will look at the smaller players, which are gearing up to introduce new products in 2020.

Market Intel: Managing Diabetes With Digital Apps: Physicians' Views On Pros And Cons

With a growing number of diabetes apps on the market, patients and physicians can obtain a large amount of data to help manage the disease. In this second part of a two-part series on the blood glucose monitoring devices market, two endocrinologists express their views on the considerations and pitfalls of using apps to help manage diabetes, and they recommend specific apps.

Don’t Trust That (Femtech) App – Most Health Apps Don’t Meet ORCHA’s Standards

Of thousands of health apps, including femtech apps, reviewed by ORCHA, only 20% meet the required standards to be considered “trustworthy.”

Topics

Related Companies

UsernamePublicRestriction

Register

MT125661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel